CF Industries Posts Stellar H1 2026, Adjusted EBITDA Hits $2.18B, Raising Questions About Earnings Sustainability

What happened

CF Industries reported first-half 2026 net earnings of $1.34 billion ($8.71 per diluted share) and adjusted EBITDA of $2.18 billion, levels already approaching full-year 2024 results. The performance includes a $170 million one-time gain from a litigation settlement, which flattered net income but had minimal impact on EBITDA. The print reflects a still-tight nitrogen market, with realized prices and volumes significantly exceeding mid-cycle assumptions. However, the annualized run-rate appears unsustainable without continued global supply constraints, and the litigation gain obscures the underlying earnings trend. The results challenge the prior wait thesis, suggesting upside to fair value if current conditions persist, though cyclicality and one-time items warrant skepticism.

Implication

The blowout H1 2026 results, with adjusted EBITDA nearly matching full-year 2024, suggest that CF’s earnings power in the current cycle may be substantially higher than our base-case scenario of ~$2.0B annual EBITDA. However, the $170 million litigation settlement inflates net earnings, and the sustainability of such high EBITDA hinges on nitrogen prices staying elevated, which is contrary to consensus forecasts for moderate softening. Investors should closely watch management’s guidance for the back half and any signs of price erosion, as the stock now likely prices in a ‘higher-for-longer’ scenario. The prior ‘wait’ rating may need upgrading, but only after confirming that these results are not an outlier and that capital allocation remains disciplined amid strong cash flows. A reassessment of the bull case probability is merited, but the cyclical nature of the business still demands a margin of safety.

Thesis delta

The H1 2026 print materially exceeds the base-case earnings trajectory, suggesting CF’s normalized EBITDA may be above $2.5B rather than $2.0B. This shifts the investment thesis from wait-for-a-better-entry to potential upgrade if prices remain elevated and FCF stays above $1.7B. However, the one-time gain and the risk of mean reversion keep the call cautious near-term.